1. Home
  2. TRDA vs EVH Comparison

TRDA vs EVH Comparison

Compare TRDA & EVH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$7.08

Market Cap

274.5M

Sector

Health Care

ML Signal

HOLD

Logo Evolent Health Inc

EVH

Evolent Health Inc

HOLD

Current Price

$3.96

Market Cap

272.4M

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRDA
EVH
Founded
2016
2011
Country
United States
United States
Employees
152
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
274.5M
272.4M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
TRDA
EVH
Price
$7.08
$3.96
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
15
Target Price
$21.00
$7.93
AVG Volume (30 Days)
677.8K
2.6M
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$25,421,000.00
$907,957,000.00
Revenue This Year
$39.97
$33.89
Revenue Next Year
$50.80
$15.84
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.93
$2.10
52 Week High
$16.45
$11.92

Technical Indicators

Market Signals
Indicator
TRDA
EVH
Relative Strength Index (RSI) 37.64 57.52
Support Level $5.75 $3.68
Resistance Level $7.54 $4.20
Average True Range (ATR) 0.50 0.30
MACD 0.10 -0.06
Stochastic Oscillator 76.46 38.13

Price Performance

Historical Comparison
TRDA
EVH

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

About EVH Evolent Health Inc

Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.

Share on Social Networks: